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EDITORIAL REVIEW
Management of hyperlipidemia of kidney disease
The growing recognition that dyslipidemia is a major risk
factor for coronary heart disease (CHD) has prompted in-
creased interest in the identification and management of abnor-
malities in plasma lipids and lipoproteins [1]. This recognition
has led to the initiation of a national program for prevention of
CHD through control of high serum cholesterol and related
dyslipidemias [21. In the general population most dyslipidemia
is of dietary origin although many cases have a genetic compo-
nent. However, dyslipidemia also can be secondary to other
diseases, notably hypothyroidism, diabetes mellitus, and renal
disease. With the latter, the nephrotic syndrome, chronic renal
failure, and the post-renal transplant state frequently are ac-
companied by hyperlipidemia. Since these conditions appear to
impart increased risk for CHD, the question naturally arises
whether concomitant dyslipidemia contributes to greater risk. If
so, the best approach to control of lipid disorders becomes an
important clinical issue. The current review will examine sev-
eral aspects of dyslipidemias found in patients with nephrotic
syndrome, renal failure, and post-renal transplant, namely,
specific lipid patterns, mechanisms responsible for these pat-
terns, possible links with atherogenesis, and available data on
therapy.
Nephrotic syndrome
The major lipid abnormality in the nephrotic syndrome is an
elevation of plasma total cholesterol, or more specifically, low
density lipoprotein (LDL) cholesterol [3, 4]. Some investigators
believe that elevated cholesterol levels are an essential feature
of the nephrotic syndrome. Nephrotic patients also can have an
increase in plasma triglycerides [3]; however, hypertriglyceri-
demia commonly develops later in the course of the disease and
is not an essential component of the syndrome [3, 5—8].
The mechanisms for nephrotic hypercholesterolemia have
been studied by several investigators, but they remain to be
fully elucidated. The prevailing view is that high LDL levels are
the result of hepatic overproduction of lipoproteins containing
apolipoprotein-B-l00 (apo B) [9—11]. The precise stimulus for
lipoprotein overproduction is a matter of dispute, but almost
certainly it is related to loss of albumin [6—8] and perhaps other
macromolecules [12] in urine. Several investigations in labora-
tory animals [9, 10, 13] strongly support the mechanism of
lipoprotein overproduction, and studies in humans are in accord
[5, 14—16]. At the same time, hepatic synthesis of cholesterol
appears to be increased in the nephrotic syndrome [10, 17]; if
this response raises hepatic cholesterol content, the result may
be a down regulation of synthesis of LDL receptors [18]. Such
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a mechanism would retard clearance of LDL from the circula-
tion, and combined with lipoprotein overproduction, would
doubly raise the LDL-cholesterol concentration; the occur-
rence of a dual metabolic defect in LDL metabolism could
explain why some patients with the nephrotic syndrome have
extreme elevations of LDL cholesterol.
The hypertriglyceridemia occurring in nephrotic patients
likewise could be the result of two factors, namely, an overpro-
duction of very low density lipoproteins (VLDL) by the liver
and defective lipolysis of triglyceride-rich lipoproteins. Over-
production of lipoproteins has been reported to contribute to
elevated VLDL levels [5, 14], but we recently observed in
several patients with nephrotic syndrome that retarded lipolysis
of VLDL triglycerides was the major cause of high triglycerides
[16]. Sluggish lipolysis could result from a deficiency of lipo-
protein lipase (LPL) [7, 19—21] or hepatic triglyceride lipase
(HTGL), urinary loss of activators of LPL (such as, apolipo-
protein C-Il) [2 1—23], or perhaps the presence of circulating
inhibitors of LPL [24, 25]. Elevated plasma triglycerides in
nephrotic patients thus may be multifactorial, and at present,
the relative roles of the various factors are not well understood.
In fact, the causes of hypertriglyceridemia in the nephrotic
syndrome may be similar to those in chronic renal failure, and
these will be considered in the next section.
There is no reason to doubt that nephrotic hypercholester-
olemia can promote atherogenesis and thereby enhance risk for
CHD. High levels of LDL cholesterol are known to increase
CHD risk in a variety of conditions, and the same probably
holds for the nephrotic syndrome. Hypercholesterolemia in
most adult nephrotic patients usually has not been present for
as many years as in genetic forms of hypercholesterolemia, and
thus, the time factor must be considered when speculating
about risk imparted by nephrotic hypercholesterolemia. On the
other hand, the severity of nephrotic hypercholesterolemia may
partially offset its shorter duration. In some children or adoles-
cents, on the other hand, many years of hypercholesterolemia
may be anticipated. In any case, several reports [26—28] claim
that patients with nephrotic syndrome are at increased risk for
CHD. Whether the addition of hypertriglyceridemia to hyper-
cholesterolemia in nephrotic patients further enhances the risk
is unknown, but this possibility has been suggested [271. Re-
duced concentrations of high density lipoproteins (HDL) often
accompany elevated triglycerides, and this change too could
enhance coronary risk.
The first mode of therapy in typical patients with primary
hyperlipidemia is modification of the diet. Unfortunately, no
studies have systematically tested the efficacy of dietary ther-
apy in hypercholesterolemia due to the nephrotic syndrome.
Since LDL cholesterol often is severely elevated, dietary
therapy alone almost certainly will not "normalize" cholesterol
levels, nor is it even likely to appreciably mitigate the marked
hypercholesterolemia. Still, a decrease in intakes of saturated
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fatty acids and cholesterol, along with weight reduction in
obese patients, is a reasonable first step in management of
nephrotic hypercholesterolemia. Reductions in intakes of satu-
rated fatty acids to less than 10% of total calories and dietary
cholesterol to less than 300 milligrams per day can be recom-
mended [29]. Dietary therapy for hypercholesterolemia of
course must be carried out in accord with the overall nutritional
needs of the nephrotic patient. For example, the patient may
require a low protein diet in addition to one reduced in saturated
fatty acids and cholesterol. In most patients, maximal dietary
therapy cannot be expected to lower LDL-cholesterol levels
more than 30 to 40 mg/dl; and thus if a major reduction in LDL
concentrations is to be achieved, it will be necessary to turn to
lipid-lowering drugs.
Five drugs (or classes of drugs) have emerged as being
generally safe and effective for treatment of primary hypercho-
lesterolemia [29]. These include bile acid sequestrants, nicotinic
acid, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG CoA) reductase, fibric acids and probucol. A few studies
have been carried out with most of these drugs in various forms
of renal dyslipidemia with the notable exception of nicotinic
acid, The potential usefulness of these drugs for treatment of
nephrotic hyperlipidemia can be considered first.
Bile acid sequestrants
Bile acid sequestrants (cholestyramine and colestipol) are
nonabsorbable resins with quaternary amine groups that bind
bile acids. They sequester bile acids in the intestine and
interrupt their enterohepatic circulation. This enhances conver-
sion of cholesterol into bile acids, reduces hepatic cholesterol
content, and thereby enhances synthesis of LDL receptors [301;
the result is a decline in plasma LDL cholesterol. With doses of
8 to 20 g/day, concentrations of LDL cholesterol fall by 30 to 60
mgldl [31]. Because of their bile-acid binding properties, the
sequestrants can cause constipation at higher doses. They also
can interfere with absorption of certain drugs, notably, digoxin,
digitoxin, warfarin, thyroxine, thiazide diuretics, and beta-
adrenergic blocking agents. In some patients they raise triglyc-
eride levels, which might be a drawback for nephrotic patients
with a tendency to hypertriglyceridemia.
Bile acid sequestrants definitely will lower LDL levels in
patients with the nephrotic syndrome. For example, Valeré et al
[32] reported that 15 to 25 g per day of colestipol produced a
32% decrease in LDL cholesterol in seven patients with ne-
phrotic hypercholesterolemia. More recently, Rabelink et al
[33] indicated that 8 g twice daily of cholestyramine in nephrotic
patients lowered LDL cholesterol by 19%. These reductions in
LDL levels are similar to those reported in patients with
primary hypercholesterolemia [31]. Although these findings are
encouraging, LDL-cholesterol concentrations in both studies
remained markedly elevated even with relatively high doses of
resins [32, 33]. Bile acid sequestrants, therefore, when used
alone are inadequate therapy in most patients with nephrotic
hypercholesterolemia. As will be discussed below, however,
they may be useful in combined drug therapy.
Nicotinic acid
Nicotinic acid is a potent LDL-lowering drug when used for
primary dyslipidemia [34]. It has the further advantage of
reducing VLDL-triglyceride levels and raising HDL-choles-
terol. These actions should be particularly beneficial for ne-
phrotic patients who have mixed hyperlipidemia and low HDL-
cholesterol levels. Nicotinic acid acts to inhibit the secretion of
apo B-containing lipoproteins by the liver [35, 36]. This mech-
anism is particularly attractive for the nephrotic syndrome
because it should counteract the major cause of dyslipidemia,
namely, the overproduction of lipoproteins.
Although nicotinic acid has theoretical advantages for ne-
phrotic patients, the drug has not been studied systematically
for this purpose. Unfortunately, nicotinic acid causes a variety
of side effects that may mitigate its usefulness. It can cause
flushing and itching of the skin, gastrointestinal distress, hepatic
dysfunction, worsening of hyperglycemia in patients with un-
derlying glucose intolerance, and increases in uric acid. Some
of these side effects can be minimized by initiating the drug at
very low doses and increasing the dose slowly [29]. The
lipid-lowering response is proportional to the dose, and the dose
must be raised to at least 1.5 grams three times daily to be
maximally effective. More research is needed to determine the
effectiveness of nicotinic acid in the nephrotic syndrome, but at
the clinical level the drug should be used cautiously in nephrotic
patients because its side effects may be worse than usual.
HMG CoA reductase inhibitors
HMG CoA reductase inhibitors are a new class of drugs that
act by inhibiting a rate-limiting enzyme in cholesterol synthesis,
namely, HMG CoA reductase [37]. They act primarily in the
liver to inhibit cholesterol synthesis and thereby enhance for-
mation of LDL receptors [38, 39]. These receptors recognize all
apo B-containing lipoproteins and promote direct hepatic clear-
ance of both VLDL and LDL. This effect accounts for their
action to lower plasma levels of both LDL cholesterol and
VLDL triglycerides. In patients with primary hypercholester-
olemia, the HMG CoA reductase inhibitors will reduce LDL-
cholesterol levels by 40 to 80 mg/dl [40]. Recent studies [16, 33,
41] indicate that these drugs have a similar potency for LDL
lowering in patients with the nephrotic syndrome. Lovastatin is
the only reductase inhibitor currently approved in the United
States, but pravastatin and simvastatin are related drugs that
may be approved in the future.
The HMG CoA reductase inhibitors have proven to be
remarkedly free of side effects in hypercholesterolemic individ-
uals who are otherwise healthy. In some patients they induce
various gastrointestinal complaints, mild but reversible in-
creases in liver enzymes, and insomnia. The most worrisome
side effect to date has been myopathy. This can occur in three
forms. Some patients complain of myalgias and excessive
fatigue but have no laboratory evidence of myopathy. Others
have moderate elevations of creatine kinase with or without
myalgia; these elevations generally resolve by reducing the
dose or discontinuing the drug altogether. Finally, rare patients
manifest severe myopathy with extreme elevations of creatine
kinase, myoglobinuria, and even acute renal failure [42]. Fac-
tors predisposing to severe myopathy include concomitant use
of cyclosporine, gemfibrozil, and nicotinic acid or the presence
of liver disease. Since the active metabolites of reductase
inhibitors are excreted primarily by the liver, interference with
their transport into bile, by either concomitant drug therapy or
disease, can raise blood levels and predispose to severe myop-
athy [37].
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Fibric acids
Fibric acids include clofibrate, gemfibrozil, fenofibrate,
bezafibrate, and ciprofibrate, the first two of which are pres-
ently available in the United States. The fibric acids apparently
interfere with hepatic synthesis of both triglycerides and cho-
lesterol and thus potentially lower both lipids in the plasma [431.
The triglyceride-lowering effect is observed mainly in hypertri-
glyceridemic patients, whereas cholesterol lowering occurs
principally in hypercholesterolemic individuals [44]. Reduction
in plasma triglycerides may be accentuated by enhanced activ-
ity of LPL. Unfortunately, the cholesterol-lowering action is
relatively modest, and the fibric acids hold little promise for
treatment of the severe hypercholesterolemia of the nephrotic
syndrome. Further, the action of these drugs to modify choles-
terol metabolism results in an increased secretion of cholesterol
into bile and thus enhances the risk for cholesterol gallstones
[45]. Their use for therapy of elevated plasma triglycerides will
be discussed in the section on chronic renal failure.
Probucol
This cholesterol-lowering drug causes a moderate reduction
of LDL-cholesterol levels, in the range of 20 to 30 mg/dl [461. It
acts mainly to promote the clearance of LDL from the circula-
tion [46]. Unfortunately, probucol also reduces HDL-choles-
terol levels, but this potentially unfavorable side effect may be
offset by its action to inhibit the oxidation of LDL [47]. Recent
studies suggest that oxidation of LDL in the artery wall is a key
step for uptake by tissue macrophages and formation of foam
cells [48], the hallmark of the atherosclerotic lesion. Prevention
of LDL oxidation in the arterial wall by probucol thus could
retard development of atherosclerosis. Furthermore, a recent
study [49] has shown that probucol lowers LDL cholesterol
levels in nephrotic patients at least as well as in primary
hypercholesterolemia, and it generally is without serious side
effects. In spite of these potential advantages, however, the
drug cannot be considered first-line therapy because of its
modest LDL-lowering action.
Combined drug therapy
Use of a single drug for treatment of severe hypercholester-
olemia of the nephrotic syndrome is rarely adequate to 'nor-
malize" cholesterol concentrations; consideration therefore
can be given to using drugs in combination. Combined therapy
has provided enhanced efficacy in primary dyslipidemia, but it
has not been tried in nephrotic hyperlipidemia. The combina-
tion of bile acid sequestrants and nicotinic acid, which is highly
effective in primary hyperlipidemia [50, 51], is theoretically
attractive because it will efficiently lower both cholesterol and
triglycerides and raise HDL. Unfortunately, many patients
cannot tolerate this combination of drugs for prolonged periods
because of adverse or unpleasant reactions. The combination of
bile acid sequestrants and HMG CoA reductase inhibitors likely
will be better tolerated by most patients and has the further
advantage of producing a greater reduction in LDL-cholesterol
levels [52—54]. Indeed, this may be the best available combina-
tion for severe nephrotic hypercholesterolemia. Nicotinic acid
and/or fibric acids probably should not be used in combination
with HMG CoA reductase inhibitors in patients with the ne-
phrotic syndrome because of the high risk for severe myopathy
[42]. Probucol can be combined with reductase inhibitors, and if
oxidation of LDL proves to be a key intermediate step in
atherogenesis, probucol would become particularly attractive
for nephrotic patients in whom LDL levels cannot be "normal-
ized" by other drugs.
Chronic renal failure
The major dyslipidemia of patients with chronic renal failure
is an increase in plasma triglycerides [55—59]. Approximately
30% of patients with renal failure have hypertriglyceridemia.
Generally triglyceride levels are between 200 and 600 mg/dl,
and elevations occur mainly in VLDL, although intermediate
density lipoproteins (IDL) may be increased and LDL are
enriched in triglycerides [60]. Increased triglyceride levels
occur both before and during hemodialysis, and it has not been
proven that hemodialysis will consistently mitigate the severity
of the hypertriglyceridemia.
The mechanisms for elevated triglycerides in chronic renal
failure have not been determined fully, but most data suggest
that reduced lipolysis of triglyceride-rich lipoproteins is the
predominant defect [61—65]. Several reports indicate that there
is a deficiency of LPL [57— 66—69], of HTGL [57, 68—70], or both
[57, 67, 69]. Enrichment of LDL particles with triglycerides
suggests a partial deficiency of HTGL [60]. Circulating inhibi-
tors of lipolytic enzymes may be yet another factor impairing
lipolysis of triglycerides [25]. Repeated injections of heparin in
hemodialysis patients may temporarily deplete stores of LPL
and HTGL, but they are not a major cause of persistent
hypertriglyceridemia. If high carbohydrate diets are consumed,
they can enhance hepatic synthesis of VLDL triglycerides, as
will obesity, and they will further raise triglyceride levels. An
elevation in circulating triglycerides can be held responsible for
the decrease in HDL-cholesterol concentrations that is ob-
served in many patients with renal failure [55, 57, 67, 69—73].
The hypertriglyceridemia of the nephrotic syndrome may have
the same origins as that of chronic renal failure. This possibility
must be considered because VLDL triglycerides are slowly
hydrolyzed in nephrotic patients as well as in those with renal
failure. In some patients, hypertriglyceridemia in patients with
renal failure may be accentuated by secondary factors—obe-
sity, diabetes mellitus, corticosteroids, and beta-adrenergic
blocking agents.
Chronic renal failure appears to increase the risk for CHD
[74—80]. The contribution of hypertriglyceridemia to this in-
creased risk is conjectural. Most investigators believe that
raised CHD risk reported for renal failure patients is multifac-
tonal in origin; several factors including hypertension, smok-
ing, electrolyte imbalances, hemostatic abnormalities and cir-
culating arterial "toxins" may contribute in addition to
dyslipidemia. Furthermore, some epidemiologists [81] have
questioned whether hypertriglyceridemia is a "risk factor" for
CHD. If not, there would be no justification to treat elevated
plasma triglycerides in chronic renal failure. Certainly triglyc-
erides per se contribute little to the lipid component of athero-
sclerotic plaques. On the other hand, high triglycerides are
known to raise the concentrations of other lipoproteins that
apparently do promote atherogenesis [82]. These "athero-
genic" lipoproteins include chylomicron remnants [831, VLDL
remnants IDL [84—88], and small, dense LDL [82, 89]; more-
over, hypertriglyceridemia frequently reduces levels of "pro-
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tective" HDL [90, 911. Thus, whereas elevated plasma triglyc-
erides per se may not be atherogenic, they nonetheless
probably increase coronary risk through their effects on other
lipoproteins. If this is true, then therapeutic reduction of
triglyceride concentrations could retard the development of
atherosclerosis in patients with chronic renal failure.
In spite of a theoretical benefit from reducing triglyceride
levels in patients with renal failure, effective and safe modes of
therapy whereby this aim can be adequately achieved do not
exist at present. Dietary modifications, specifically weight
reduction in obese patients and reduced carbohydrate intakes,
will minimize overproduction of VLDL triglycerides by the
liver and thereby will lower plasma triglyceride levels [92—94].
These dietary changes, however, will not alter the underlying
defect, namely, sluggish lipolysis of VLDL triglycerides, and
they cannot be expected to eliminate elevated triglycerides for
most patients. In contrast, exercise seemingly promotes catab-
olism of VLDL triglycerides, but the value of exercise has not
been tested in patients with chronic renal failure.
Dietary modification, although generally not adequate, is
easy to recommend [95], but use of triglyceride-lowering drugs
is more difficult to justify in hypertriglyceridemic patients with
chronic renal failure. First, the specific contribution of elevated
triglycerides to heightened CHD risk in this condition is un-
known. Second, a beneficial effect of drugs for reducing CHD
risk in patients with renal failure has not been demonstrated in
a clinical trial. Third, the extent to which drugs will reduce
concentrations of 'atherogenic" lipoproteins in renal failure
patients remains to be documented; and fourth, their long-term
safety has not been proven. For these reasons, it may be
prudent to withhold drug therapy for mild-to-moderate hyper-
triglyceridemia in patients with chronic renal failure until a
better demonstration of benefit has been provided through
clinical trials. Nonetheless, a brief review of experience with
these drugs may be of interest.
The drugs that have been most tested for lipid lowering in
chronic renal failure are the fibric acids. A major action of these
drugs is to enhance the activity of LPL, and consequentially,
they tend to correct the underlying cause of elevated triglycer-
ides in this condition. Several studies have been carried out in
renal failure patients with the fibric acids including clofibrate
[67, 96—99], gemfIbrozil [69], and bezafibrate [73]. Most studies
indicate that a significant reduction in triglyceride levels can be
obtained, and HDL-cholesterol levels will often rise as well.
Since the fibric acids are excreted largely by the kidneys, their
dose must be reduced considerably to prevent toxicity. One
form of toxicity is myopathy accompanied with high levels of
creatine kinase. Although some patients with chronic renal
failure are able to tolerate fibric acids without developing
myopathy, several investigators [96, 99] suggest that the risk is
too high to use these drugs routinely in hypertriglyceridemic
patients with renal failure, Not only is the risk of myopathy
relatively high, but their effectiveness for specifically reducing
the danger of CHD in renal disease patients has not been
determined. For the present, it may be prudent to avoid their
use in clinical practice, although further research on their
potential is warranted.
Other lipid-lowering drugs have not been tested in patients
with chronic renal failure. The side effects of nicotinic acid
probably preclude its use. Bile acid sequestrants are not appro-
priate because they tend to enhance hypertriglyceridemia. No
benefits can be visualized at present for the use of probucol.
Perhaps the most promising are the HMG CoA reductase
inhibitors; by promoting direct removal of remnant lipopro-
teins, they could decrease the levels of these "atherogenic"
lipoproteins in plasma. However, reductase inhibitors remain to
be tested for this purpose. Omega-3 polyunsaturated fatty acids
found in fish oils can lower triglyceride levels; still, they
primarily decrease secretion rates for VLDL triglycerides and
do not modify the underlying lipolytic defect. Besides, they
may increase the likelihood of bleeding by interfering with
platelet function. Their use in chronic renal failure cannot be
recommended at this time because they have not been ade-
quately studied for relative advantages and disadvantages.
Post-renal transplant hyperlipidemia
Another renal condition in which dyslipidemia has been
reported is post-kidney transplant. A variable pattern of hyper-
lipidemia has been noted; some patients exhibit hypertriglycer-
idemia, others hypercholesterolemia, and still others mixed
hyperlipidemia [100—108]. The mechanisms for multiple lipopro-
tein patterns after renal transplantation are not well understood,
but most investigators believe that several factors contribute.
Perhaps the most important among these is concomitant corti-
costeroid therapy [103—108]. Corticosteroids seemingly en-
hance peripheral resistance to the action of insulin, raise insulin
levels, and stimulate the synthesis of VLDL triglycerides. This
mechanism can account for higher serum triglycerides in post-
transplant patients, but it does not explain why some individu-
als exhibit pure hypercholesterolemia. Indeed, the rise in
cholesterol level is one of the most interesting features of
post-transplant hyperlipidemia; high cholesterol concentrations
arc rarely seen in patients with chronic renal failure before
transplantation. Although some investigators [1091 suggest that
other immunosuppressive drugs, especially cyclosporine, used
after transplantation contribute to the hyperlipidemia, this
possibility has not been confirmed with certainty.
Limited information is available on treatment of post-trans-
plant hyperlipidemia. Weight reduction in obese patients may
cause some lowering of triglyceride and cholesterol levels
[110-111]. Reduction in intake of saturated fatty acids and
cholesterol may do likewise [Ill]. Alternate-day corticosteroid
therapy may help in some patients but not all [112—114]. Better
control of diabetes, if present, should reduce lipid levels to
some extent. Use of lipid-lowering drugs may be accompanied
by too high a risk for side effects in post-transplant patients. For
example, use of lovastatin in combination with cyclosporine is
contraindicated because of the high risk for severe myopathy.
Fibric acids (clofibrate and gemfibrozil) also can produce myop-
athy in the presence of renal disease. Bile acid sequestrants can
worsen hypertriglyceridemia, and they have not been shown to
be effective for lowering cholesterol concentrations after kidney
transplant.
Conclusions
The hypercholesterolemia of the nephrotic syndrome proba-
bly enhances risk for CHD, and if the long-term outlook for a
patient is otherwise good, attempts should be made to reduce
the LDL-cholesterol level. The HMG CoA reductase inhibitors
appear to be the most promising type of drug for this purpose.
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To ensure their long-term safety in nephrotic patients, however,
further studies of greater duration will be required. Use of
reductase inhibitors in combination with bile acid sequestrants
is particularly attractive because the combination should 'nor-
malize" LDL levels in most patients with severe hypercholes-
terolemia. Unfortunately, available treatment modalities for
hypertriglyceridemia of chronic renal failure leave much to be
desired. The fibric acids are a logical choice, but the risk of
toxicity may be too high to employ them on a routine basis. A
safer course for present may be to avoid use of lipid-lowering
drugs in patients with renal failure and to concentrate efforts on
modifying the diet and increasing exercise. The same approach
can be recommended for management of dyslipidemia occur-
ring in patients after renal transplantation.
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